- Home
- FERA vs LCTX Comparison
FERA vs LCTX Comparison
Compare FERA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- LCTX
- Stock Information
- Founded
- FERA 2024
- LCTX 1990
- Country
- FERA Cayman Islands
- LCTX United States
- Employees
- FERA N/A
- LCTX N/A
- Industry
- FERA
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FERA
- LCTX Health Care
- Exchange
- FERA Nasdaq
- LCTX Nasdaq
- Market Cap
- FERA 317.7M
- LCTX 274.0M
- IPO Year
- FERA 2025
- LCTX N/A
- Fundamental
- Price
- FERA $10.16
- LCTX $1.39
- Analyst Decision
- FERA
- LCTX Strong Buy
- Analyst Count
- FERA 0
- LCTX 4
- Target Price
- FERA N/A
- LCTX $4.25
- AVG Volume (30 Days)
- FERA 9.3K
- LCTX 1.3M
- Earning Date
- FERA 01-01-0001
- LCTX 11-13-2025
- Dividend Yield
- FERA N/A
- LCTX N/A
- EPS Growth
- FERA N/A
- LCTX N/A
- EPS
- FERA N/A
- LCTX N/A
- Revenue
- FERA N/A
- LCTX $10,914,000.00
- Revenue This Year
- FERA N/A
- LCTX N/A
- Revenue Next Year
- FERA N/A
- LCTX $178.80
- P/E Ratio
- FERA N/A
- LCTX N/A
- Revenue Growth
- FERA N/A
- LCTX 76.43
- 52 Week Low
- FERA $9.87
- LCTX $0.37
- 52 Week High
- FERA $10.20
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- LCTX 67.78
- Support Level
- FERA N/A
- LCTX $1.20
- Resistance Level
- FERA N/A
- LCTX $1.42
- Average True Range (ATR)
- FERA 0.00
- LCTX 0.07
- MACD
- FERA 0.00
- LCTX 0.01
- Stochastic Oscillator
- FERA 0.00
- LCTX 87.50
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.